Abbott’s Xience V trial is positive

Abbott’s clinical trials of its Xience V Everolimus Eluting Coronary Stent System prove it to be more beneficial than previous devices.

Compared to the Taxus Express2 and the Liberte ? both Paclitaxel-Eluting products ? the latest development from the healthcare company showed more advantages for the patient two to three years after administration.

The studies also revealed it did not have as many adverse side effects, with patients experiencing fewer heart attacks, repeat procedures or death during 36 months after treatment.

All of these areas are especially important in trials and it is promising that the product performed well on these key issues, explained Professor Patrick W Serruys from the Erasmus University Hospital in Rotterdam,

“What’s even more impressive is that the clinical differences between Xience V and Taxus continue to widen between two and three years, confirming the long-term safety and efficacy of Xience V,” he commented.

Executive vice-president of medical devices at Abbott John Capek remarked the latest investigations prove the stent to be an “excellent option” for patients.

On April 15th, the firm will announce its first-quarter 2009 financial results.